Who Supplies Irbesartan to India from BULGARIA

Importing finished pharmaceutical formulations containing Irbesartan into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs be registered and approved before distribution. The registration process involves obtaining an Import Registration Certificate from CDSCO, which necessitates submission of Form 40 or 41, depending on the nature of the product. Additionally, an Import License from the Directorate General of Foreign Trade (DGFT) is required. The registration timeline can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory workload. For formulations under HS Code 30049079, specific requirements include detailed product information, manufacturing licenses, and stability data. It's crucial to ensure that the product complies with the Indian Pharmacopoeia standards and that the manufacturing facility holds a valid Good Manufacturing Practice (GMP) certificate.

Upon arrival in India, imported pharmaceutical formulations containing Irbesartan are subject to quality testing by CDSCO-approved laboratories. Each batch must be accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, is essential to demonstrate the product's shelf-life under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity of the product and ensure it meets all regulatory requirements. Failure to provide satisfactory documentation or if the product fails quality testing can result in delays, rejections, or destruction of the consignment.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical products to enhance drug safety and efficacy. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially affecting the volume of finished formulation imports. Bilateral agreements between India and Bulgaria have facilitated smoother trade relations, with mutual recognition of GMP certifications and streamlined approval processes for Bulgarian pharmaceutical products. These developments aim to bolster domestic production while maintaining the quality and safety of imported medicines.

India imports finished Irbesartan formulations to meet the demand for branded and patented products not manufactured domestically. Specific dosage forms, such as extended-release tablets, may not be produced locally, necessitating imports. The market size for Irbesartan in India is substantial, with a growing patient population requiring hypertension management. Despite the presence of domestic manufacturers, the import dependency persists due to the need for diverse formulations and consistent quality assurance.

The Basic Customs Duty (BCD) for pharmaceutical products under HS Code 30049079 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is levied on the BCD, resulting in a total duty of 11%. Integrated Goods and Services Tax (IGST) is applicable, with rates varying based on the product's classification and value. Anti-dumping duties may apply if the product is deemed to be imported at unfairly low prices. Exemption notifications can reduce or eliminate certain duties, but these are subject to change and require verification with the latest customs notifications.

India sources finished Irbesartan formulations from Bulgaria due to the country's adherence to international quality standards and competitive pricing. Bulgaria's pharmaceutical industry is known for its robust manufacturing capabilities and compliance with Good Manufacturing Practice (GMP) certifications. While other suppliers like China, Germany, and the United States also export Irbesartan formulations to India, Bulgaria's strategic position and trade agreements with India enhance its competitive advantage. Bulgaria's share in the Indian market for Irbesartan formulations is growing, reflecting increasing trust in its pharmaceutical exports.

India imports finished Irbesartan formulations from Bulgaria due to the country's compliance with international quality standards and the availability of specialized dosage forms not produced domestically. Bulgaria's pharmaceutical industry offers patented formulations and technology-licensed products that meet the therapeutic needs of the Indian market. The importation of these formulations ensures a diverse and reliable supply of Irbesartan, catering to various patient requirements.

When compared to other origins like China, Germany, and the United States, Bulgaria offers a competitive advantage in terms of quality and regulatory compliance. Bulgaria's adherence to Good Manufacturing Practice (GMP) standards and its strategic location within the European Union facilitate efficient trade with India. While other countries may offer lower prices, Bulgaria's consistent quality and reliability make it a preferred source for finished Irbesartan formulations.

Indian importers face several supply chain risks when sourcing finished Irbesartan formulations from Bulgaria, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory developments, conduct thorough quality checks, and establish contingency plans for shipping delays. Historically, there have been no significant shortages reported in this supply chain, indicating a stable import scenario.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial exposure.

4.